Broad-Spectrum Antiviral Therapeutics: From Conserved Vulnerabilities to Mechanism-Guided Drug Discovery
Pharmaceuticals · 02.11.2026 · 19 (11) · 1741
DOI: 10.3390/ph19111741 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceuticals, online erschienen am 02.11.2026. Verfasst von Xinya Yang und 5 weiteren Autor:innen. Die Arbeit nennt 111 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, National Key Research and Development Plan of China, Ningbo Natural Science Foundation.
Abstract (Originalsprache)
The continuous emergence and re-emergence of viral pathogens pose persistent threats to global health. Although direct-acting antivirals (DAAs) have transformed the treatment of multiple viral infections, their spectrum is often constrained by viral diversity and the rapid emergence of drug resistance. Host-targeted antivirals (HTAs) provide a complementary strategy by targeting cellular processes exploited by diverse viruses, but their development is limited by host toxicity and context-dependent viral dependence. Here, we propose that antiviral breadth is not an intrinsic property of a drug or target but an emergent phenotype governed by four interconnected determinants: conservation of biological vulnerability, viral dependency, chemical tractability, and therapeutic selectivity. We examine how these determinants shape the antiviral spectrum of both virus- and host-directed strategies and discuss key translational barriers, including metabolic compensation, viral adaptation, and the gap between in vitro activity and in vivo efficacy. We further propose a mechanism-guided framework that integrates viral evolution, host dependency, pharmacological tractability, intracellular exposure, and rational combination strategies to enable more predictive broad-spectrum antiviral discovery. Rather than seeking a universal antiviral, this framework supports the development of modular therapeutic strategies tailored to viral dependency, tissue context, and pharmacological constraints.
Förderung
- National Natural Science Foundation of China
- National Key Research and Development Plan of China
- Ningbo Natural Science Foundation
- the Summit Advancement Disciplines of Zhejiang Province
- Science Technology Department of Wenzhou
Zitieren
APA
Yang, X., Wang, B., Zhang, Y., Xie, Y., Li, Z., & Sun, P. (2026). Broad-Spectrum Antiviral Therapeutics: From Conserved Vulnerabilities to Mechanism-Guided Drug Discovery. Pharmaceuticals, 19(11), 1741. https://doi.org/10.3390/ph19111741
Vancouver
Yang X, Wang B, Zhang Y, Xie Y, Li Z, Sun P. Broad-Spectrum Antiviral Therapeutics: From Conserved Vulnerabilities to Mechanism-Guided Drug Discovery. Pharmaceuticals. 2026;19(11):1741. doi:10.3390/ph19111741
BibTeX
@article{Yang2026,
author = {Yang, Xinya and Wang, Baifeng and Zhang, Yucheng and Xie, Yinli and Li, Zhiyong and Sun, Peng},
title = {Broad-Spectrum Antiviral Therapeutics: From Conserved Vulnerabilities to Mechanism-Guided Drug Discovery},
journal = {Pharmaceuticals},
year = {2026},
volume = {19},
number = {11},
pages = {1741},
doi = {10.3390/ph19111741}
}
EUVIMED